Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

• Francesca Conradie,
• Anna Vassall,
• Norbert Ndjeka,
• Gabriela Beatriz Gomez,
• Mariana Siapka,
• Anna Marie Celina Garfin,
• Nino Lomtadze,
• Zaza Avaliani,
• Nana Kiria,
• Shelly Malhotra,
• Sarah Cook-Scalise,
• Sandeep Juneja,
• Daniel Everitt,
• Melvin Spigelman

Affiliations

Francesca Conradie

Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa

Anna Vassall

Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

Norbert Ndjeka

National TB Programme, South Africa Department of Health, Pretoria, Gauteng, South Africa

Gabriela Beatriz Gomez

Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

Mariana Siapka

Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

Anna Marie Celina Garfin

National Tuberculosis Control Program, Bureau of Disease Prevention and Control, Department of Health, Manila, The Philippines

Nino Lomtadze

Department of TB Surveillance and Strategic Planning, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

Zaza Avaliani

Department of TB Surveillance and Strategic Planning, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

Nana Kiria

Department of TB Surveillance and Strategic Planning, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

Shelly Malhotra

TB Alliance, New York, New York, USA

Sarah Cook-Scalise

TB Alliance, New York, New York, USA

Sandeep Juneja

TB Alliance, New York, New York, USA

Daniel Everitt

TB Alliance, New York, New York, USA

Melvin Spigelman

TB Alliance, New York, New York, USA